Testing vismodegib plus atezolizumab for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign the study consent form and follow the study plan.
- You have confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer must have progressed during or within 6 months after platinum chemotherapy.
- You need a follow-up plan for your cancer measurements (measurable or evaluable disease).
- Your body must be able to handle treatment based on blood tests and organ function (recent lab results within 14 days).
- You must be able to swallow capsules and avoid pregnancy during treatment and the required follow-up period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (sacituzumab govitecan plus bevacizumab) works better than the usual chemotherapy for ovarian cancer that has come back after platinum treatment and PARP inhibitor maintenance. It may offer a new option for people with certain genetic markers (BRCA mutations or HRD).
This trial tests a combination of drugs (adebrelimab, chemotherapy, bevacizumab, and fluzoparib) for ovarian cancer that has returned after a period of remission. It may help by using the immune system and targeted therapy to attack cancer cells.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Hear when a new Platinum-Resistant Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.